Compare PACB & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACB | PRTC |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | 485 | 56 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.8M | 423.3M |
| IPO Year | 2010 | N/A |
| Metric | PACB | PRTC |
|---|---|---|
| Price | $1.48 | $17.42 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.67 | N/A |
| AVG Volume (30 Days) | ★ 5.8M | 16.3K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $93,468,000.00 | N/A |
| Revenue This Year | $11.32 | N/A |
| Revenue Next Year | $12.14 | N/A |
| P/E Ratio | ★ N/A | $8.09 |
| Revenue Growth | ★ 3.04 | N/A |
| 52 Week Low | $0.96 | $14.50 |
| 52 Week High | $2.73 | $19.92 |
| Indicator | PACB | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 51.72 |
| Support Level | $1.40 | $16.67 |
| Resistance Level | $1.79 | $18.70 |
| Average True Range (ATR) | 0.09 | 0.76 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 89.77 | 30.55 |
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.